Status:
COMPLETED
Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients
Lead Sponsor:
Tameside General Hospital
Conditions:
COVID-19
Vitamin D Deficiency
Eligibility:
All Genders
18+ years
Brief Summary
The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitami...
Detailed Description
STUDY DESIGN Arm 1: Hospital in-patients with a clinical diagnosis of COVID-19 This will be an observational cohort study of patients hospitalised at Tameside General Hospital with a clinical diagnosi...
Eligibility Criteria
Inclusion
- ARM 1 - hospital in-patients
- In-patient admitted to Tameside General Hospital.
- Clinical diagnosis of COVID-19 - not necessary for SARS-CoV-2 swab to be positive.
- Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.
Exclusion
- Final clinical diagnosis NOT COVID-19.
- ARM 2 - prospective primary care case-control study
- Inclusion Criteria:
- Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 8 2020
Estimated Enrollment :
986 Patients enrolled
Trial Details
Trial ID
NCT04386044
Start Date
June 1 2020
End Date
September 8 2020
Last Update
May 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tameside Hospital NHS Foundation Trust
Ashton-under-Lyne, Greater Manchester, United Kingdom, OL6 9RW